Ionctura is a clinical-stage biotech company focused on the development of novel anti-cancer ion channel inhibitors. The company leverages its expertise in ion channel pharmacology to target difficult-to-treat cancers with a focus on solid tumors.

iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance.

iOnctura’s pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone.  

iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3Kδ to treat Treg-driven tumors; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor to treat cancer associated fibroblast (CAF) driven tumors. 

iOnctura is backed by specialist institutional investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.

For more information, please visit www.ionctura.com


FONGIT Innovation Fund

KWF Kankerbestrijding

Health Holland

European Innovation Council

M Ventures

VI Partners

Schroder Adveq

3B Future Health Fund

Inkef

iOnctura

Ionctura

COM:IONCTURA

Ionctura

Analysis Not Available